Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance
Reference number: TA284
Published: 22 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)
25 March 2013
(323.89 Kb 34 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 March 2013